MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.hrtlng.2026.102804

Медицинская библиотека · Heart & lung : the journal of critical care · 2026

Reassessment of risk profiles through weight and BMI changes in idiopathic pulmonary fibrosis.

Bozkus Fulsen, Deniz Pelin Pınar, Uzer Fatih, Yazıcı Onur, Dikiş Özlem Şengören, Tapan Utku, Gülen Şule Taş, Uçar Hatice Arzu, Sarıbaş Ertan, Özyürek Berna Akıncı, Akkurt Esma Sevil, Dolmuş Tunahan, Demirci Nilgün Yılmaz, Hanta İsmail, Keskin Olgun, Kısmet Gözde Kalbaran, Günlüoğlu Gülşah, Süleymanova Samira, Okutan Oğuzhan, Coşkun Funda

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease in which weight loss and low BMI have emerged as adverse prognostic indicators. However, longitudinal data on early weight change-particularly in patients receiving antifibrotic therapy-remain limited. This study examined the relationship between first-year weight change and clinical outcomes in a multicenter IPF cohort from Türkiye.

METHODS

This retrospective study analyzed 428 patients diagnosed with IPF between 2019 and 2024 across 12 centers. Weight at diagnosis and one year, clinical characteristics, antifibrotic treatment, pulmonary function tests, 6MWD, and survival outcomes were evaluated. Annual weight change was categorized as no loss, <5% loss, or ≥5% loss; significant weight loss was defined as ≥5%.

RESULTS

Among 428 patients (mean age 68.3 ± 8.0 years; 82% male), 78.5% experienced significant weight loss during follow-up. At the end of the first year, baseline BMI and the prevalence of diabetes mellitus decreased progressively with increasing weight loss, with the lowest values observed in patients with ≥5% weight loss (p = 0.018 and p = 0.023, respectively). In parallel, greater weight loss at the end of the first year was associated with worse pulmonary function, reflected by declining FVC (L and % predicted) and DLCO (% predicted), while rates of dietitian evaluation increased markedly, reaching the highest level in the ≥5% weight loss group (all p ≤ 0.036). During follow-up, patients with ≥5% weight loss lost an average of 6.20 kg, while those without loss gained 0.22 kg (p < 0.001). Greater annual FVC decline occurred in both weight-loss groups (p = 0.018 and p = 0.005), whereas DLco decline was similar across groups. Antifibrotic use-especially nintedanib-was more frequent among those with ≥5% loss (p = 0.010). Weight loss was not associated with mortality or hospitalization, but correlated with greater functional deterioration. Age and baseline BMI independently predicted weight change.

CONCLUSIONS

Early weight loss is common in IPF and is associated with accelerated functional decline, independent of antifibrotic therapy. Routine weight monitoring may provide additional prognostic value and supports incorporating body composition into IPF risk stratification.

Для цитирования: Bozkus Fulsen, Deniz Pelin Pınar, Uzer Fatih, Yazıcı Onur, Dikiş Özlem Şengören, Tapan Utku, Gülen Şule Taş, Uçar Hatice Arzu, Sarıbaş Ertan, Özyürek Berna Akıncı, Akkurt Esma Sevil, Dolmuş Tunahan, Demirci Nilgün Yılmaz, Hanta İsmail, Keskin Olgun, Kısmet Gözde Kalbaran, Günlüoğlu Gülşah, Süleymanova Samira, Okutan Oğuzhan, Coşkun Funda. Reassessment of risk profiles through weight and BMI changes in idiopathic pulmonary fibrosis.. Heart & lung : the journal of critical care. 2026. DOI: 10.1016/j.hrtlng.2026.102804.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.